Salvage HD-MTX-based re-induction for relapsed PCNSL

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-RITUXIMAB` `DRUG-METHOTREXATE` `DRUG-VINCRISTINE` `DRUG-PROCARBAZINE`

ID	`REG-R-MPV-SALVAGE-PCNSL`
Type	Regimen
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-DLBCL-2024` `SRC-NCCN-CNS-2025`

Notes

For relapsed PCNSL after initial HD-MTX induction with documented prior chemosensitivity. Re-induction with R-MPV → consolidation autoSCT (thiotepa-based, IELSG32) preferred for fit. WBRT alternative for ASCT-ineligible (cognitive toxicity caveat). Ibrutinib emerging salvage option.

Used By

Indication

IND-PCNSL-2L-RMPV-SALVAGE - IND-PCNSL-2L-RMPV-SALVAGE